BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever. The company was founded in 1986 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioCryst projects $1B peak sales for ORLADEYO, eyes global expansion

BioCryst Pharmaceuticals showcased strong performance driven by ORLADEYO's success, with a clear path towards $1 billion in peak sales and global expansion.
While facing challenges such as delays in BCX10013's development and managing expenses, the company remains focused on maximizing product value and market opportunities.
Opportunities lie in expanding ORLADEYO's market presence, exploring international sales, and investing in R&D for future growth and innovation.

BioCryst projects strong revenue growth for ORLADEYO, faces regulatory hurdles

BioCryst Pharmaceuticals demonstrates strong performance and revenue growth potential for ORLADEYO, aiming to exceed $320 million guidance for the year.
Challenges include revenue impact from free drug complexities and regulatory delays, with opportunities in global market expansion and pediatric therapy development.
The company's focus on patient care, financial stability, and long-term sales outlook positions BioCryst for continued growth and success in the pharmaceutical market.

BioCryst Pharmaceuticals on track to hit $320M in ORLADEYO sales

BioCryst Pharmaceuticals is confident in reaching $320 million in ORLADEYO sales this year through patient growth. Q3 and Q4 revenue growth expected to be steady, with opportunities for expansion outside the U.S.

BioCryst's ORLADEYO excels in Q3, faces challenges and growth opportunities

BioCryst Pharmaceuticals continues to see strong performance with ORLADEYO revenue and patient growth.
The company faces challenges with co-payment assistance programs and competitive market dynamics.
Opportunities lie in market education, pediatric patient expansion, and maintaining a competitive edge.
Despite expected expense increases, BioCryst remains focused on value creation and long-term growth.

BioCryst reports robust earnings, eyes $1B peak revenue for ORLADEYO

BioCryst Pharmaceuticals showcased strong financial performance and positive long-term data for ORLADEYO, aiming for $1 billion in global peak revenue.
While facing challenges with patient retention and market access, the company emphasized its growing product portfolio and accelerated path to profitability.
Opportunities lie in achieving profitability by 2026, improving market access, and leveraging therapy efficacy to drive revenue growth and market expansion.

BioCryst Pharmaceuticals excels in Q1, eyes Japanese market expansion

BioCryst Pharmaceuticals delivered strong Q1 results driven by ORLADEYO sales, raising revenue guidance for 2024 and advancing pipeline programs.
While facing challenges in expenses and gross to net margins, the company's strategic focus on market expansion and pipeline development presents growth opportunities.
Overall, BioCryst Pharmaceuticals shows promise with a balanced patient mix, strong market research projections, and high strategic interest in its flagship product.

BioCryst's ORLADEYO excels, revenue guidance raised amidst operational achievements

BioCryst Pharmaceuticals showcased robust performance in Q2 driven by ORLADEYO, with strong revenue growth and operational achievements.
Despite challenges like product portfolio diversification and profitability targets, the company's strategic focus on ORLADEYO's market expansion and revenue guidance increase highlights growth potential.
Opportunities lie in further leveraging ORLADEYO's success, exploring new market segments, and enhancing market strategies to drive sustained growth and market leadership.

BioCryst Pharmaceuticals reports robust revenue growth and pipeline advancements

BioCryst Pharmaceuticals delivered strong financial results driven by ORLADEYO's performance, showcasing market acceptance and revenue growth.
The company's pipeline advancements and proactive management approach position them well for future growth and product portfolio expansion.
While facing challenges in sustaining momentum and managing competition, BioCryst Pharmaceuticals has opportunities to capitalize on market demand and optimize operational strategies for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired employees stock options to purchase an aggregate of 18,200 shares, and restricted stock units (RSUs) covering an aggregate of 12,750 shares, of BioCryst common stock. The options and RSUs were granted as of October 31, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Anthony Doyle - CFO Helen Thackray - Chief R&D Officer Jinky Rosselli - Chief Data and Insights Officer Conference Call Participants Nick Lenard - JPMorgan Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Maury Raycroft - Jefferies Stacy Ku - TD Cowen Liisa Bayko - Evercore ISI Gena Wang - Barclays Serge Belanger - Needham & Company Operator Good day and Welcome to the BioCryst Third Quarter 2024 Earnings Call. All participants will be in listen-only mode.

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript

BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates

The consensus price target hints at a 79.5% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5%

RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2024 financial results on Monday, November 4, 2024.

BioCryst to Report Third Quarter 2024 Financial Results on November 4

RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU), including significant reductions in hospitalizations, emergency room visits and use of on-demand therapies, after beginning treatment with ORLADEYO.

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

BioCryst (BCRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BioCryst (BCRX) Upgraded to Buy: Here's Why

—Potential best-in-class targeted treatment for Netherton syndrome is company's first protein therapeutic to advance to the clinic—

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has awarded BioCryst up to a $69 million contract for the procurement of up to 95,625 doses over a five-year period of RAPIVAB® (peramivir injection) for the treatment of influenza.

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

INTENDED FOR CANADIAN AUDIENCES ONLY TORONTO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for oral, once-daily PrORLADEYO® (berotralstat), which is approved in Canada for the routine prevention of attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older.

BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks

RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of six posters, including the first interim real-word evidence from the APeX-N trial, and new data highlighting the value of shared decision making (SDM) between healthcare providers (HCPs) and their hereditary angioedema (HAE) patients to provide optimal patient outcomes.

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2024 Earnings Call Transcript August 5, 2024 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Anthony Doyle - CFO Helen Thackray - Chief R&D Officer Conference Call Participants Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Chris Raymond - Piper Sandler Gena Wang - Barclays Maury Raycroft - Jefferies Stacy Ku - TD Cowen Jon Wolleben - JMP Securities Serge Belanger - Needham & Company Operator Good day and welcome to the BioCryst Second Quarter 2024 Earnings Call. All participants will be in listen-only mode.

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript

The mean of analysts' price targets for BioCryst (BCRX) points to a 99.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?

BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago.

BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates

—Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— —Company generates GAAP operating profit of $8.8 million in second quarter ($21.9 million non-GAAP operating profit)— —Pipeline continues to advance— RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update.

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

ACM Research

Krispy Kreme

Edgewise Therapeutics

Gigacloud Tech

Dorian LPG

McEwen Mining

Small-capitalization companies represent high-risk endeavors. At the same time, they generally carry higher reward potential.

7 Small-Cap Stocks to Buy for Large-Scale Gains

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know

RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2024 financial results on Monday, August 5, 2024.

BioCryst to Report Second Quarter 2024 Financial Results on August 5

BioCryst Pharmaceuticals develops complement-mediated and rare disease treatments using a structure-guided drug design process. The company's pipeline also includes promising drug candidates in pivotal phases and pre-clinical stages. The company relies heavily on Orladeyo, which represents 95.8% of its total revenues.

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BioCryst (BCRX) Upgraded to Strong Buy: Here's Why

The average of price targets set by Wall Street analysts indicates a potential upside of 92.6% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older.

ORLADEYO® (berotralstat) Approved in Peru

Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and more tolerable HAE prophylaxis options Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and more tolerable HAE prophylaxis options

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Valencia, Spain from May 31 to June 3, 2024.

News for BioCryst Pharmaceuticals Stock (BCRX)